Сarbohydrate metabolism disorders and their outcomes in the long-term period in hospitalized patients with COVID-19

BACKGROUND: Diabetes mellitus (DM) is a predisposing factor for the development of many infectious complications. Numerous studies have demonstrated the association of hyperglycemia in patients having DM with a high risk of a more unfavorable course of COVID-19. However, hyperglycemia is often detected in patients with a COVID-19 not having anamnesis of DM. The following remains unclear: the etiological factors causing such disorders of carbohydrate metabolism, the persistence of these disorders and the characteristics of the course, as well as their comparative effect on the outcomes of COVID-19 and the further prognosis of patients.

AIM: To study the prevalence and nature of carbohydrate metabolism disorders in patients with moderate to severe course of COVID-19, as well as 6 months after it.

MATERIALS AND METHODS: Hospitalized patients with a confirmed diagnosis of COVID-19 of moderate and severe course of the disease were examined. There were no medical interventions outside recommendations of patient management. The observation was carried out during two time periods: inpatient treatment of a COVID-19 and 6 months after discharge. The following were evaluated: anamnesis data, the level of fasting plasma glucose; HbA1c, the results of computed tomography of the lungs, the drug therapy taken in all patients. Descriptive statistics methods were used to evaluate the parameters.

RESULTS: The study included 280 patients with a median age of 61.5±14,2 years. During the disease, a violation of  carbohydrate metabolism was detected in 188 people (67%), the remaining patients (33%) made up the normoglycemia group. Patients with hyperglycemia were stratified in a following way: a group with an established diagnosis of DM before COVID -19 included — 56 people (20%), a group with steroid-induced hyperglycemia (SIH) — 95 people (34%), a group of stress- induced hyperglycaemia — 20 people (7%), with undiagnosed diabetes — 17 people (6%). In the postcovid period (after 6 months), the normal level of glycemia in the same sample group was observed in 199 people (71.4%); 8 people (3%) were diagnosed with new cases of DM. The mortality rate was 10 people (3.6%) in the group of SIH (8 people) and undiagnosed DM (2 people).

CONCLUSION: The use of glucocorticoids in hospitalized patients with COVID-19 leads to high incidence of SIH, which has reversible character. About 6% among hospitalized patients with a COVID-19 had undiagnosed DM and were not receiving antihyperglycemic therapy. The highest mortality was noted in the group of SIH, which allows us to conclude that SIH worsens the prognosis of patients to the greatest extent. Patients with newly diagnosed hyperglycemia, regardless of the level of hyperglycemia, are characterized by a more unfavorable course.

1. Coronavirus 2019-nCoV, CSSE [Internet]. Coronavirus 2019-nCoV Global Cases by Johns Hopkins CSSE [cited 03.10.22]. Available from: https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6

2. World Health Organization. Coronavirus Disease (COVID-19) Dashboard [Internet] 2020 [cited 03.10.22]. Available from: https://web.archive.org/web/20201012153053if_/https://covid19.who.int/table

3. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. N Engl J Med. 2020;382(13):1199-1207. doi: https://doi.org/10.1056/NEJMoa2001316

4. Salukhov VV, Kharitonov MA, Kryukov EV, et al. Topical issues of diagnostics, examination and treatment of patients with covid-19-associated pneumonia in various countries and continents. Medical Council. 2021;382(21):96-102. (In Russ.). doi: https://doi.org/10.21518/2079-701X-2020-21-96-102

5. WHO. Novel coronavirus [Internet]. China. Jan 12, 2020. [cited Jan 19, 2020]. Available from: http://www.who.Int/csr/don/12-january-2020-novel-coronavirus-china/en/

6. Kukushkin GV, Starostina EG. Infections in diabetics (lecture). RMJ. 2016;24(20):1327-1333. (In Russ.)].

7. Yan Y, Yang Y, Wang F, et al. Clinical characteristics and outcomes of patients with severe covid-19 with diabetes. BMJ Open Diabetes Res Care. 2020;8(1):e001343. doi: https://doi.org/10.1136/bmjdrc-2020-001343

8. Coppelli A, Giannarelli R, Aragona M, et al. Hyperglycemia at Hospital Admission Is Associated With Severity of the Prognosis in Patients Hospitalized for COVID-19: The Pisa COVID-19 Study. Diabetes Care. 2020;43(10):2345-2348. doi: https://doi.org/10.2337/dc20-1380

9. Yang J-K, Lin S-S, Ji X-J, Guo L-M. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010;47(3):193-199. doi: https://doi.org/10.1007/s00592-009-0109-4

10. Pal R, Bhadada SK. COVID-19 and diabetes mellitus: An unholy interaction of two pandemics. Diabetes Metab Syndr. 2020;14(4):513-517. doi: https://doi.org/10.1016/j.dsx.2020.04.049

11. Kharitonov MA, Salukhov VV, Kryukov EV, et al. Viral pneumonia: a new look at an old problem (review). Med Counc. 2021;47(16):60-77. (In Russ.). doi: https://doi.org/10.21518/2079-701X-2021-16-60-77

12. Dedov II, Mokrysheva NG, Shestakova MV, et al. Glycemia control and choice of antihyperglycemic therapy in patients with type 2 diabetes mellitus and COVID-19: a consensus decision of the board of experts of the Russian association of endocrinologists Diabetes Mellitus. 2022;25(1):27-49. (In Russ.). doi: https://doi.org/10.14341/DM12873]

13. Avdeev SN, Adamyan LV, Alekseeva EI, et al. Temporary guidelines. The prevention, diagnosis and treatment of the new coronavirus infection (COVID-19). Ministry of Health of the Russian Federation. Version 9. 26.10.2020 (In Russ.). Доступно по: https:// static-0.rosminzdrav.ru/system/attachments/attaches/000/050/584/original/03062020_МR_COVID-19_v7.pdf

14. Dedov II, Shestakova MV, Maiorov Ayu, et al. Clinical recommendations. Standards of specialized diabetes care. 10th Edition. Moscow: Ministry of Health of the Russian Federation; 2021. (In Russ.). Доступно по: http://cr.rosminzdrav.ru/#!/recomend/970

15. Alimov AV, Khaydarova FA, Alieva AV, et al. Hyperglycemia on the background of treatment of COVID-19-associated pneumonia using glucocorticoids. Juvenis scientia. 2021;7(2):5-11. (In Russ.). doi: https://doi.org/10.32415/jscientia_2021_7_2_5-11

16. Das S, Rastogi A, Harikumar KVS, et al. Diagnosis and management considerations in steroid-related hyperglycemia in COVID-19: A position statement from the endocrine society of India. Indian J Endocrinol Metab. 2021;25:4-11. doi: https://doi.org/10.4103/ijem.ijem-227-21

17. Pasquel FJ, Lansang MC, Dhatariya K, Umpierrez GE. Management of diabetes and hyperglycaemia in the hospital. Lancet Diabetes Endocrinol. 2021;9(3):174-188. doi: https://doi.org/10.1016/S2213-8587(20)30381-8

18. Roberts A, James J, Dhatariya K, et al. Management of hyperglycaemia and steroid (glucocorticoid) therapy: a guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group. Diabet Med. 2018;35(8):1011-1017. doi: https://doi.org/10.1111/dme.13675

19. Gulliford MC, Charlton J, Latinovic R. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care. 2006;29(12):2728-2729. doi: https://doi.org/10.2337/dc06-1499

20. Fong AC, Cheung NW. The high incidence of steroid-induced hyperglycaemia in hospital. Diabetes Res Clin Pract. 2013;99(3):277-280. doi: https://doi.org/10.1016/j.diabres.2012.12.023

21. Tatalovic M, Lehmann R, Cheetham M, et al. Management of hyperglycaemia in persons with non-insulin-dependent type 2 diabetes mellitus who are started on systemic glucocorticoid therapy: a systematic review. BMJ Open. 2019;9(5):e028914. doi: https://doi.org/10.1136/bmjopen-2019-028914

22. Dobravc Verbič M, Gruban J, Kerec Kos M. Incidence and control of steroid-induced hyperglycaemia in hospitalised patients at a tertiary care centre for lung diseases. Pharmacol Reports. 2021;73(3):796-805. doi: https://doi.org/10.1007/s43440-021-00234-2

23. American Diabetes. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021. Diabetes Care. 2021;44(S1):S15-S33. doi: https://doi.org/10.2337/dc21-S002

24. Aberer F, Hochfellner DA, Sourij H, Mader JK. A Practical Guide for the Management of Steroid Induced Hyperglycaemia in the Hospital. J Clin Med. 2021;10(10):2154. doi: https://doi.org/10.3390/jcm10102154

25. Potemkin VV, Starostina EG. Neotlozhnaia endokrinologiia. Moscow: MIA; 2008. (In Russ.).

26. Kononenko IV, Smirnova OM, Mayorov AY, Shestakova MV. Classification of diabetes. World Health Organization 2019. What’s new? Diabetes Mellitus. 2020;23(4):329-339. (In Russ.). doi: https://doi.org/10.14341/DM12405